You cannot register for this webinar

Atara is focused on applying Epstein-Barr virus T-cell biology and novel chimeric antigen receptor (CAR) technologies to enter new frontiers of cell therapy for patients with cancer and autoimmune diseases. With cutting edge-science and differentiated approach, we are the first company in the world to receive regulatory approval for an allogeneic T-cell immunotherapy with the approval of Ebvallo™ by the European Commission. Atara also recently submitted the first allogeneic T-cell therapy (tab-cel) BLA to the U.S. FDA and, if approved, tab-cel would be the first approved therapy in the U.S. for EBV+ post-transplant lymphoproliferative disease. Atara is headquartered in Southern California.